In this regard, the combination of adavosertib with ceralasertib or with an inhibitor of the anti‐apoptotic protein BCL‐XL led to synergistic anti‐tumour effects with a significant therapeutic window in vivo and in a TNBC cell model, respectively.223, 224. This evidence concerns the gene BCL2L1 and neoplasm.